结直肠癌治疗的新方向——靶向治疗休眠期癌细胞

2015-07-12 MedSci MedSci原创

结直肠癌治疗的新方向——靶向治疗休眠期癌细胞在美国,结直肠癌是致死的第二大癌症,但是大多数患者死于癌症转移的其他部位,如肝脏,而不是死于肠道部分。通常结直肠癌患者的常规治疗效果并不佳,主要是由于疾病确诊时癌细胞已经扩散至其他器官。癌细胞可以休眠的方式长时间存在身体的其他部位,直至被激活增殖形成转移性肿瘤,最终导致个体的死亡。目前,据由澳大利亚墨尔本大学发表在Stem Cell的一项研究表明,结直肠

在美国,结直肠癌是致死的第二大癌症,但是大多数患者死于癌症转移的其他部位,如肝脏,而不是死于肠道部分。

通常结直肠癌患者的常规治疗效果并不佳,主要是由于疾病确诊时癌细胞已经扩散至其他器官。癌细胞可以休眠的方式长时间存在身体的其他部位,直至被激活增殖形成转移性肿瘤,最终导致个体的死亡。

目前,据由澳大利亚墨尔本大学发表在Stem Cell Reports的一项研究表明,结直肠癌的治疗可以采取一个新的方向——针对处于休眠状态的结直肠癌细胞而不仅针对处于激活状态的结直肠癌细胞。

该研究中,研究人员阐述了他们是如何找到一种方法可以控制导致结直肠癌细胞扩散的干细胞行为。

该研究结果围绕着Frizzled7的激活,Frizzled7是接受细胞外信号的受体或细胞表面蛋白。

既往的研究已经确立了一种肠道干细胞——隐窝基底干细胞或CRCs,因为它是唯一一个可激活另一种受体Lgr5的细胞,故能被特异性识别——在激活癌细胞中发挥着重要的作用。当肠道细胞受损时,这些干细胞可帮助肠上皮或内层细胞再生。细胞需让“ Wnt”信号通过干细胞的表面受体进入至细胞内部才能发挥这个功能。


允许Wnt信号通过的受体称为“Frizzled”,它存在10种不同的类型。

但是在此研究之前并不清楚Lgr5特异性干细胞(CRCs)中哪种Frizzled受体可允许Wnt信号通过以引发癌症。研究人员最后将其命名为Frizzled7。

墨尔本肿瘤生物学实验室主任,首席研究员Elizabeth Vincan教授,解释道:

“如果当细胞处于休眠状态时敲除Frizzled7,那么细胞便不能够促进肿瘤细胞的生长。现在的目标是尝试获得处于休眠状态的细胞,这代表了癌症靶向治疗的一个转变。”

Elizabeth Vincan表示,研究的下一步是找到一种针对Frizzled7的方法,并开发出一种与当前治疗相结合的抗体治疗方法。

原始出处:

Flanagan DJ, Phesse TJ, Barker N, Schwab RH, Amin N, Malaterre J, Stange DE, Nowell CJ, Currie SA, Saw JT, Beuchert E, Ramsay RG, Sansom OJ, Ernst M, Clevers H, Vincan E. Frizzled7 functions as a wnt receptor in intestinal epithelial lgr5(+) stem cells. Stem Cell Reports. 2015 May 12;4(5):759-67.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2016-03-22 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-18 hjj0000

    非常实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-14 Jianghuiqin

    期待进一步探索!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-14 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1668056, encodeId=f45f166805652, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Tue Mar 22 03:51:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33030, encodeId=c315330300a, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f12104305, createdName=hjj0000, createdTime=Sat Jul 18 09:18:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32718, encodeId=6e0932e182f, content=期待进一步探索!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jul 14 11:26:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252038, encodeId=706412520383d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452761, encodeId=219d1452e6163, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Jul 14 10:51:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32603, encodeId=3bd132603a7, content=是有价值的策略。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jul 13 14:28:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-13 medcardio

    是有价值的策略。

    0

相关资讯

Cell:激活APC基因可诱导结直肠癌细胞转变为正常的细胞

Science Daily:癌症治疗的新希望——激活某特定的基因可诱导肿瘤细胞转变为正常的细胞抗癌治疗通常包括杀死肿瘤细胞,然而,据6月18日发表在Cell上的一项研究表明,仅通过激活一个单一的基因就可以诱导癌细胞转为正常的组织。研究人员发现,恢复成正常细胞的人结直肠癌细胞在小鼠体内停止生长并在短短4天内重新建立起正常的肠道功能。值得注意的是,两周内肿瘤消失,数月后也未有肿瘤复发的迹象。该发现为修

NEJM:TAS-102对难治性转移性结直肠癌的临床效果

背景:主要在日本进行的早期临床试验已经表明,抗癌药物TAS-102(一种结合三氟胸苷和地匹福林盐酸盐的口服剂)对于难治性大肠癌的治疗是有效的。研究人员进行了3期临床试验以进一步评估在全球范围内TAS-102对病人的功效和安全性。    方法:在这个双盲研究中,研究人员以2:1的比例随机分配800例患者,分别接受TAS-102或安慰剂。主要终点是总生存期。 

Int J Epidemiol:女性身高越高,患结直肠癌的风险越大

Int J Epidemiol:女性身高越高,患结直肠癌的风险越大近日有研究表明,身高与女性结直肠的发生有关,该研究与2015年3月20日在线发表于Int J Epidemiol.无论男性还是女性,身高越高其发生癌症的风险越高。对于结直肠癌(CRC)目前还不清楚不同性别的身高差异是其发生的直接因素,混杂因素亦或者是观察性研究中的偏倚。本研究中,我们采用孟德尔随机化研究以评估身高与CDC发生风险之间

Cancer Discov.:新型Sym004 抗-EGFR抗体混合物用于难治性结直肠癌的临床研究

背景:在表皮生长因子受体(EGFR)抑制剂的抵抗下肿瘤生长可能保持EGFR-依从性,其是通过补偿性的配体上调和新创基因突变进行介导的。Sym004是靶标为非重叠EGFR抗原的两个抗体混合物。临床试验:在临床前模型中,Sym004可使EGFR显著的内化和降解,在配体的存在下转化为更上一级的生长抑制作用。在临床I期试验阶段,剂量升级期间,我们观察到基于机制的剂量限制反应:3级皮肤毒性和低镁血症。在剂量

eLife:科学家揭开抑癌又促癌扩散的双刃剑蛋白的神秘面纱

来自加利福尼亚大学的研究人员近日研究发现了一种新型的细胞信号通路,该通路或许可以有效控制结直肠癌的发生和发展,该通路中的一种关键蛋白被认为可以有效预测结直肠癌患者的癌症生存率,相关研究刊登于国际杂志eLife上。 这种特殊蛋白名为“散乱蛋白”,其富含亮氨酸残基或Daple基因,机体中几乎所有的健康细胞都会产生散乱蛋白,而且该蛋白可以帮助不同组织中的细胞来进行多种生物学过程的协调,比如器官发育和维

JAMA:高质量的结肠镜筛查可降低死亡率

近期发表在JAMA的新研究发现,通过结肠镜筛查发现更多的腺瘤可以使一生中结直肠癌的发生风险和死亡风险降低50%-60%,而并不需要花费更多的费用。“腺瘤检查率(ADR)被推荐作为结肠镜检查质量指示因子。”该研究的主要作者、荷兰Erasmus MC大学医学中心的Reinier G. S. Meester如是说,“然而,ADR与基于结肠镜的结直肠癌筛查带来的长期获益及花费的关系,目前尚不明确。”为了评